Leftagraph

Every financial statement,
one clean chart.

Search any US-listed company. Data straight from SEC filings.

PROBuild your own list with the screener

INMUNE BIO INC. (INMB) financial statements

Number look wrong? Tell us

Data table
PROBuild your own list with the screener

INMUNE BIO INC. (INMB), most recent 12 months reported: revenue $50K, net loss $18.42M, free cash flow -$23.62M. Latest balance sheet on file: liquid cash $24.75M. From SEC filings. Others in Biological Products, (No Diagnostic Substances): CARDIFF ONCOLOGY, INC. · aTYR PHARMA INC · VivoSim Labs, Inc. · AIM ImmunoTech Inc. · Senti Biosciences Holdings, Inc. · Creative Medical Technology Holdings, Inc. · Acumen Pharmaceuticals, Inc. · Abpro Holdings, Inc.

Stock screener

Watchlist